<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039099</url>
  </required_header>
  <id_info>
    <org_study_id>AP101-02</org_study_id>
    <secondary_id>2020-005971-11</secondary_id>
    <nct_id>NCT05039099</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AL-S Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AL-S Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Multiple Ascending Dose (MAD) study is to evaluate the safety,&#xD;
      tolerability, PK, and PD of AP-101 in participants with fALS and sALS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>From start of the study up to Week 48</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other situations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, Electrocardiograms (ECGs)</measure>
    <time_frame>From start of the study up to Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of AP-101 in Serum</measure>
    <time_frame>Predose up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Drug Concentration (Tmax) of AP-101 in Serum</measure>
    <time_frame>Predose up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve from Time Zero to Infinite (AUC [0-inf]) of AP-101 in Serum</measure>
    <time_frame>Predose up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Time tau (Dosing Interval) (AUC[0-tau]) of AP-101 in Serum</measure>
    <time_frame>Predose up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration (AUC[0-tlast]) of AP-101 in Serum</measure>
    <time_frame>Predose up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AP-101 Levels in the Cerebrospinal Fluid (CSF) up to Week 48</measure>
    <time_frame>Baseline, up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in the Cerebrospinal Fluid (CSF) up to Week 48</measure>
    <time_frame>Baseline, up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in Plasma up to Week 48</measure>
    <time_frame>Baseline, up to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AP-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP-101 is administered by IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered by IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP-101</intervention_name>
    <description>Participants receive multiple ascending doses of AP-101 by intravenous infusion (IV).</description>
    <arm_group_label>AP-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive multiple ascending doses of placebo by IV.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants must adhere to contraception restrictions&#xD;
&#xD;
          -  Female participants of childbearing potential must adhere to contraception&#xD;
             restrictions&#xD;
&#xD;
          -  Have possible, clinically probable, clinically probable-laboratory supported or&#xD;
             definite familial or sporadic ALS in accordance with the El-Escorial criteria or who&#xD;
             have a diagnosis of ALS as defined by the Gold Coast Criteria; progressive motor&#xD;
             impairment documented by history or repeated clinical examination, preceded by normal&#xD;
             motor development, and presence of upper and lower motor neuron dysfunction in at&#xD;
             least 1 body region or lower motor neuron dysfunction in at least 2 body regions and&#xD;
             investigations excluding other conditions&#xD;
&#xD;
          -  In familial ALS participants, a confirmed pathogenic superoxide dismutase 1 (SOD1)&#xD;
             mutation&#xD;
&#xD;
          -  Onset of symptoms (i.e, weakness) within past 24 months prior to screening, at the&#xD;
             time of obtaining informed consent&#xD;
&#xD;
          -  Have slow vital capacity (SVC) of greater than or equal to (&gt; or =) 50 percentage (%)&#xD;
             of predicted values&#xD;
&#xD;
          -  Absence of bilevel positive airway pressure (BiPAP)/proportional assist ventilation&#xD;
             (PAV) for symptoms attributable to ALS. Use of a CPAP for pre-existing conditions will&#xD;
             be allowed&#xD;
&#xD;
          -  If on riluzole, must be on a stable dose&#xD;
&#xD;
          -  If on edaravone, must have completed 2 cycles and are expected to remain on the same&#xD;
             dose throughout the study&#xD;
&#xD;
          -  Able to provide informed consent which includes compliance with the requirements and&#xD;
             restrictions&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling&#xD;
&#xD;
          -  Have clinical laboratory test results within the normal reference range for the&#xD;
             population or study site, or results with acceptable deviations that are judged to be&#xD;
             not clinically significant by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated or currently participating in another clinical trial within 12 weeks&#xD;
             of baseline (Day 1)&#xD;
&#xD;
          -  Have undergone a tracheostomy for ALS symptoms&#xD;
&#xD;
          -  Are on nasal intermittent positive pressure ventilation (NIPPV) &gt;4 hours per day for&#xD;
             the treatment of ALS related symptoms&#xD;
&#xD;
          -  Have other causes of neuromuscular weakness&#xD;
&#xD;
          -  Have cognitive impairment, severe disease in the cardiovascular, hematological, renal&#xD;
             system, neurodegenerative disease, pulmonary disorder, or psychiatric illness&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Have been exposed to any antisense treatment targeting SOD1 within 6 months of the&#xD;
             baseline visit&#xD;
&#xD;
          -  Have undergone stem cell therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>AL-S Pharma SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director: AL-S Pharma SA</last_name>
    <phone>3176517036</phone>
    <email>choruspharma@lists.lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego, ACTRI</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-243-1319</phone>
      <email>jravits@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>John Ravits</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYC - New York Medical College /Hospital for Special Surgery (HSS)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>646-797-8917</phone>
      <email>LangeD@HSS.EDU</email>
    </contact>
    <investigator>
      <last_name>Dale Lange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALS clinic at the Kaye Edmonton Clinic, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>AB T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>780-248-1089</phone>
      <email>wendyj@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Wendy Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>ON N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>519-663-3597</phone>
      <email>Christen.Shoesmith@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Christen Shoesmith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital / Dr Genge</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>514-398-3868</phone>
      <email>maximeberube@sympatico.ca</email>
    </contact>
    <investigator>
      <last_name>Maxime Bérubé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studieenheten Akademiskt specialistcentrum, SLSO</name>
      <address>
        <city>Stockholm</city>
        <zip>113 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+46725487410</phone>
      <email>caroline.ingre@sll.se</email>
    </contact>
    <investigator>
      <last_name>Caroline Ingre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Northern Sweden (NUS)</name>
      <address>
        <city>Umeå</city>
        <zip>SE- 901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+46907852372</phone>
      <email>peter.andersen@umu.se</email>
    </contact>
    <investigator>
      <last_name>Peter Munch Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Sporadic Amyotrophic Lateral Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

